The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer

Immunotherapy encourages the recipient’s own immune response to destroy cancer cells, and current evidence suggests that immunotherapies may be most beneficial in early metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T is the first therapeutic cancer vaccine to be approved by bot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mouraviev, Vladimir, Mariados, Neil, Albala, David, Concepcion, Raoul S, Shore, Neal D, Sims, Robert B, Emberton, Mark, Pieczonka, Christopher M
Formato: Artigo
Idioma:Inglês
Publicado em: MedReviews, LLC 2014
Assuntos:
Treatment Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4191632/
https://ncbi.nlm.nih.gov/pubmed/25337042
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados